Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States (2015)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/JAHA.114.001505
- Subjects: INFARTO DO MIOCÁRDIO (PREVENÇÃO E CONTROLE); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; PLAQUETAS SANGUÍNEAS (ANORMALIDADES); ARTERIOSCLEROSE (TERAPIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of the American Heart Association
- ISSN: 2047-9980
- Volume/Número/Paginação/Ano: v. 4, n. art., e001505, 9 p. 2015
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
MAGNANI, Giulia et al. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, v. 4, n. art., p. 9 2015, 2015Tradução . . Disponível em: https://doi.org/10.1161/JAHA.114.001505. Acesso em: 09 jan. 2026. -
APA
Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., et al. (2015). Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, 4( art.), 9 2015. doi:10.1161/JAHA.114.001505 -
NLM
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1161/JAHA.114.001505 -
Vancouver
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1161/JAHA.114.001505 - Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial
- The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes
- P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction
Informações sobre o DOI: 10.1161/JAHA.114.001505 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
